▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1333 by analyst upside · 2026-11-12
PCVX
Vaxcyte, Inc.
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
+70.8%
implied upside to consensus target
Current Price $68.62
Consensus Target $117.2
Bull Target $163.0
Bear Target $75.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
8
Hold
1
Sell
0
52-Week Low $42.4
52-Week High $90.75
YTD Return +47.7%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-8.05
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $42.4
52-Week High $90.75
Current Price $68.62
Bear Target $75.0
Bull Target $163.0
● Now $68.62 ● Target $117.2
TRADING DATA
Avg Volume 2.2M
YTD Return +47.7%
Analyst Count 10
Consensus Buy
Upside to Target +70.8%
Last Updated 2026-11-12

ANALYST SUMMARY

Vaxcyte, Inc. (PCVX) is currently trading at $68.62 with a Wall Street consensus price target of $117.2, implying potential upside of 70.8% over the next 12 months. 10 analysts currently cover PCVX, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $163.0, while the most cautious has a target of $75.0.

PCVX operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 47.7% year-to-date and is currently trading near the upper end of its 52-week range of $42.4 – $90.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

DVA +21.1%
DaVita Inc.
$12B · P/E 13.6x · Hold
OSCR +15.2%
Oscar Health, Inc.
$10B · P/E 14.9x · Buy
GMED +23.9%
Globus Medical, Inc.
$10B · P/E 18.5x · Buy
UHS -0.8%
Universal Health Services, Inc.
$11B · P/E 8.2x · Hold
FMS +0.1%
Fresenius Medical Care AG
$12B · P/E 13.1x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for PCVX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald reit
Overweight → Overweight 2026-10-12 40% win rate (10 calls)
BTIG reit
Buy → Buy 2026-10-05 38% win rate (8 calls)
Needham - Reiterated
Buy → Buy 2026-10-05 20% win rate (5 calls)
Guggenheim - Reiterated
Buy → Buy 2026-10-05 62% win rate (8 calls)
B of A Securities - Reiterated
Buy → Buy 2026-09-28 Building track record
Needham reit
Buy → Buy 2026-09-25 20% win rate (5 calls)
BTIG - Reiterated
Buy → Buy 2026-02-26 38% win rate (8 calls)
Guggenheim reit
Buy → Buy 2026-02-02 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
18/30
Consensus clarity
4/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →